Historical review: Cytokines as therapeutics and targets of therapeutics

被引:127
作者
Vilcek, J
Feldmann, M
机构
[1] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London W6 8LW, England
关键词
D O I
10.1016/j.tips.2004.02.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytokine research has spawned the introduction of new therapies that have revolutionized the treatment of many important diseases. These therapeutic advances have resulted from two very different strategies. The first therapeutic strategy embodies the administration of purified, recombinant cytokines. The second relies on the administration of therapeutics that inhibit the harmful effects of upregulated, endogenous cytokines. Examples of successful cytokine therapeutics include hematopoietic growth factors (colony stimulating factors) and interferons. Prime examples of cytokine antagonists that have profoundly altered the treatment of some inflammatory disorders are agents that inhibit the effects of tumor necrosis factor (TNF). In this article, we highlight some of the studies that have been responsible for the introduction of cytokine and anti-cytokine therapies, with emphasis on the development of interferons and anti-TNIF agents.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 93 条
[11]  
BUCHAN G, 1988, CLIN EXP IMMUNOL, V71, P295
[12]  
Butler DM, 1995, EUR CYTOKINE NETW, V6, P225
[13]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[14]   USE OF MONOCLONAL-ANTIBODIES AS SENSITIVE AND SPECIFIC PROBES FOR BIOLOGICALLY-ACTIVE HUMAN GAMMA-INTERFERON [J].
CHANG, TW ;
MCKINNEY, S ;
LIU, V ;
KUNG, PC ;
VILCEK, J ;
LE, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (16) :5219-5222
[15]  
CHANPALAY V, 1989, J NEURAL TRANSM, V1, P19
[16]  
Charles P, 1999, J IMMUNOL, V163, P1521
[17]   LOCALIZATION OF TUMOR-NECROSIS-FACTOR-ALPHA IN SYNOVIAL TISSUES AND AT THE CARTILAGE PANNUS JUNCTION IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
CHU, CQ ;
FIELD, M ;
FELDMANN, M ;
MAINI, RN .
ARTHRITIS AND RHEUMATISM, 1991, 34 (09) :1125-1132
[18]  
DAVID JR, 1964, J IMMUNOL, V93, P264
[19]   LOCALIZATION OF TUMOR-NECROSIS-FACTOR RECEPTORS IN THE SYNOVIAL TISSUE AND CARTILAGE PANNUS JUNCTION IN PATIENTS WITH RHEUMATOID-ARTHRITIS - IMPLICATIONS FOR LOCAL ACTIONS OF TUMOR-NECROSIS-FACTOR-ALPHA [J].
DELEURAN, BW ;
CHU, CQ ;
FIELD, M ;
BRENNAN, FM ;
MITCHELL, T ;
FELDMANN, M ;
MAINI, RN .
ARTHRITIS AND RHEUMATISM, 1992, 35 (10) :1170-1178
[20]   TUMOR-NECROSIS-FACTOR ANTIBODY TREATMENT IN CROHNS-DISEASE [J].
DERKX, B ;
TAMINIAU, J ;
RADEMA, S ;
STRONKHORST, A ;
WORTEL, C ;
TYTGAT, G ;
VANDEVENTER, S .
LANCET, 1993, 342 (8864) :173-174